Product Information
FLUOXETINE HCL 40 MG CAPSULE is a generic product labeled by Aurobindo Pharma Limited, priced at $0.0519 per EA under NDC 59651090000. Its NADAC has been published 36 times since Jan 28, 2026.
FDA first approved this application on Jan 31, 2008. Its Orange Book therapeutic-equivalence code is AB1 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
40 mg/1
Manufacturer
Aurobindo Pharma LimitedNDC
59651090000
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
FLUOXETINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA078619FDA Approved
1/31/2008
TE Code
AB1
On Market Since
7/11/2025
Pharmacological Classes
Price Statistics
The NADAC for FLUOXETINE HCL 40 MG CAPSULE has been published 36 times since Jan 28, 2026, and over the history we have for it it has declined 13.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0519 per EA |
|---|---|
| All-time high | $0.0598 (Feb 11, 2026) |
| All-time low | $0.0499 (Aug 19, 2026) |
| 52-week high | $0.0598 |
| 52-week low | $0.0499 |
| Median price | $0.0521 |
| Average price | $0.0530 |
| Largest weekly change | -4.8% (Mar 18, 2026) |
| Weeks tracked | 36 |
| Tracking since | Jan 28, 2026 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aurobindo Pharma Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Fluoxetine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin Reuptake Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FLUOXETINE HCL 40 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for FLUOXETINE HCL 40 MG CAPSULE, manufactured by Aurobindo Pharma Limited, is $0.0519 per EA (NDC 59651090000), effective Sep 30, 2026.
How has the price of FLUOXETINE HCL 40 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for FLUOXETINE HCL 40 MG CAPSULE has declined 13.2%. It has been tracked across 36 weekly CMS publications since Jan 28, 2026.
What are the highest and lowest recorded NADAC prices for FLUOXETINE HCL 40 MG CAPSULE?
Since Jan 28, 2026, the NADAC for FLUOXETINE HCL 40 MG CAPSULE has ranged from a low of $0.0499 (Aug 19, 2026) to a high of $0.0598 (Feb 11, 2026), with a median of $0.0521 per EA.
Are there cheaper alternatives to FLUOXETINE HCL 40 MG CAPSULE?
6 manufacturers publish a NADAC-priced product with the same active ingredient and strength as FLUOXETINE HCL 40 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures FLUOXETINE HCL 40 MG CAPSULE?
FLUOXETINE HCL 40 MG CAPSULE (NDC 59651090000) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.